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Abstract Bendamustine has demonstrated clinical activity
and a favorable safety profile as monotherapy or in combina-
tion with rituximab in lymphoid malignancies. As interven-
tional trials do not always reflect clinical reality, we were
interested in the treatment modalities and the outcome of
bendamustine-based first-line therapy in patients with ad-
vanced indolent non-Hodgkin lymphoma (NHL) and mantle
cell lymphoma (MCL) in routine practice. Between April
2010 and October 2011, 324 patients were enrolled in a pro-
spective non-interventional multicenter study. Choice of the
bendamustine regimen was at the treating physician’s discre-
tion. Effectiveness was assessed by best response.Mean age at
onset of therapy was 69 years. The majority (94 %) of the
patients was treated with bendamustine in combination with
rituximab at a median bendamustine dose of 177 mg/m2 per
cycle. Most often, bendamustine was administered on days 1
and 2 (87 %) at 4-week intervals over a median of 6 cycles.
Two hundred eighty-one patients qualified for evaluation of
response. The overall response rate was 86 % (complete re-
sponse 43 %, partial response 43 %, stable disease 10 %,
progressive disease 4 %). Side effects of all grades were doc-
umented for 161 of the 323 patients (50 %), most frequently
affecting blood/bone marrow (35 %). Fifty-four (17 %) pa-
tients experienced side effects of grade 3 (15 %) or grade 4
(2 %), and two patients grade 5 toxicities. Bendamustine-
based first-line treatment of patients with advanced indolent
NHL and MCL in clinical routine practice was assessed as
effective and well tolerated in our study. Response was com-
parable to results from interventional clinical trials.
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Introduction
Non-Hodgkin lymphoma (NHL) accounts for a relevant pro-
portion of the global burden of cancer. In 2008, the worldwide
incidence of NHLwas 199,600 new cases in men and 156,300
new cases in women [1]. NHL comprises a number of hetero-
geneous entities. It is usually classified by the World Health
Organization (WHO) classification [2]. Indolent lymphomas
represent 40 % of all NHL subtypes, and follicular lymphoma
being the most frequent. They are characterized by a chronic
course of the disease with successive therapies upon occur-
rence of relapse. Mantle cell lymphoma, a subtype with a
poorer prognosis, accounts for 3–10 % of NHL [2]. For a
small proportion of patients with indolent lymphoma and lim-
ited stage I–II disease, there is a curative treatment option in
contrast to patients with advanced stage disease.
Chemoimmunotherapy is the treatment of choice in previous-
ly untreated patients with advanced indolent and mantle cell
lymphoma [3–5].
Bendamustine is an alkylating agent with a unique chemi-
cal structure containing a benzimidazole ring combining
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alkylating and purine analogue-like properties. It shows only
partial cross resistance with other alkylating agents in vitro [6,
7]. Bendamustine has shown clinical activity as a monothera-
py or in combination with rituximab in patients with relapsed
or refractory lymphoid malignancies [8–12]. Of note, there
has been a longstanding experience with bendamustine in
Germany where the drug has been approved and used for
various authorized indications. Bendamustine has become a
standard of care for the treatment of indolent lymphoma.
Guidelines of the National Comprehensive Cancer Network
(NCCN) and the European Society of Clinical Oncology
(ESMO) have adopted bendamustine as a chemotherapy stan-
dard alternative to regimens like CHOP or CVP to combine
with rituximab for the treatment of advanced indolent NHL
and mantle cell lymphoma [3–5].
Just recently, a randomized phase III trial in 549 patients
with newly diagnosed stages III or IV indolent or mantle cell
lymphoma demonstrated a significantly longer median
progression-free survival (PFS) with bendamustine (90 mg/
m2 on days 1 and 2, q4w) plus rituximab compared to R-
CHOP (69.5 months vs. 31.2 months; hazard ratio 0.58,
95 % confidence interval (CI) 0.44–0.74; p<0.0001). Overall
response rate (ORR) did not differ between the two treatment
groups and was 93 % for bendamustine and rituximab. The
combination of bendamustine plus rituximab was significant-
ly better tolerated than R-CHOP [13].
It is a commonplace that prospectively randomized, con-
trolled trials provide the highest level of evidence for compar-
isons of alternative types of treatment and for defining stan-
dards of care. Yet, it is also undisputed that clinical trials are
prone to selection and do not always reflect clinical reality. We
explored the effectiveness and safety as well as treatment mo-
dalities of bendamustine therapy in the actual Breal-life^ clin-
ical practice of first-line treatment of indolent NHL andmantle
cell lymphoma.
Patients and methods
Study design and objectives
This prospective, non-interventional, multicenter study was
performed to document the routine use of bendamustine in
the first-line treatment of patients with advanced indolent
non-Hodgkin lymphoma as perWHO criteria [2] to get further
insight into therapy, effectiveness, and safety of bendamustine
in actual clinical practice. Treatment regimens, dosing, and
treatment modifications were recorded. Effectiveness was de-
termined by documentation of best response which was
assessed by the investigator as per local standard. Side effects
of bendamustine were assessed according to the National Can-
cer Institute (NCI) Common Terminology Criteria for
Adverse Events (CTCAE) version 3.0. and comorbidity by
the Charlson comorbidity score [14].
The study was approved by an appropriate ethics commit-
tee. All patients had to provide signed informed consent be-
fore enrollment.
Patient population
Patients were eligible if they had a diagnosis of advanced
indolent NHL (excluding chronic lymphocytic leukemia
(CLL)) or mantle cell lymphoma according to WHO classifi-
cation [2] with indication for systemic therapy and the deci-
sion for a bendamustine-based therapy before enrollment.
There had to be no prior treatment with chemotherapy, inter-
feron, or rituximab. Other main exclusion criteria were severe
liver damage, icterus, persistent severe myelosuppression or
abnormalities of peripheral blood count, major surgery within
30 days before treatment, infections, uncontrolled cardiac dis-
ease, and pregnancy or lactation.
Treatment
It was at the treating physician’s discretion which
bendamustine-based regimen to choose for the individual pa-
tient in compliance with the former national marketing autho-
risation of bendamustine [15].
Documentation and statistical analysis
Data on patient characteristics, history and prior treatment of
lymphoma, lymphoma characteristics, treatment with
bendamustine, response, side effects of bendamustine, diag-
nostic procedures, hospitalizations, and further therapies
planned were documented in an electronic case report form.
Treatment was documented until progression or the end of
therapy with bendamustine, whatever occurred first. The
scheduled observation period was 6 months. Patients were
followed for further 12 weeks to continue assessment of side
effects.
All efforts were undertaken to achieve a complete docu-
mentation status, covering the results that had been actually
investigated. However, the non-interventional character did
not allow further influence. Complete documentation status
was finally obtained for 95 % of patients.
The observation period of our non-interventional study was
stopped in December 2011 due to a change in marketing au-
thorization [7, 15]. Statistical analysis was descriptive. Mean
values, standard deviations, median, and minimum and max-
imum values are reported for continuous variables. Categori-
cal variables are reported as absolute numbers and as relative
proportions. ORR and disease control rate (DCR) are reported
with 95%CI. The effects of potentially confounding variables
were estimated by logistic regression models.
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Results
Analysis sets
Between April 2010 and October 2011, 324 patients were
enrolled in 57 German centers. Patients who had received at
least one dose of bendamustine were included in the safety
analysis set (n=323). For the general analysis set (n=307), 16
additional patients with a diagnosis of CLL or aggressive
lymphoma were excluded. Different analysis sets were neces-
sary for response rate (n=281) and treatment duration (n=
277), respectively, as the observation period and/or
bendamustine therapy for some patients was not completed
at the end of the study on 31 December 2011 (Fig. 1).
Patient and tumor characteristics
Complete patient and tumor characteristics of all patients from
the general analysis set are listed in Table 1. Details on prog-
nostic information are displayed in Table 2. Histology of fol-
licular lymphoma (FL) was most common (50 %), followed
by marginal zone lymphoma (MZL, 17 % incl. MALT lym-
phoma), immunocytoma (IC, 15 %), and MCL (12 %). Mean
age at onset of therapy was 68.6 years. Patients with FL were
younger than patients with other lymphoma entities (mean age
65.3 vs. 71.9 years, p<0.0001). In contrast, 78 % of patients
with MCL were older than 70 years (mean age: 74.2 years).
The Charlson score was lower in patients with FL vs. non-FL
histology (mean score 0.38 vs. 0.8, p=0.0003) and higher in
patients receiving bendamustine monotherapy vs. combina-
tion therapy (mean score 1.57 vs. 0.55, p=0.0003). The pa-
tients presented with a mean body mass index of 26 (median:
25).
One hundred and ninety-two (63 %) patients had at least
one relevant concomitant disease. Most frequent diseases
were hypertension (34 %), other tumor diseases (10 %), dia-
betes mellitus (9 %), and chronic lung disease (5 %).
Treatment
Overall median time to treatment from primary diagnosis was
8.6 weeks and 9.9 in FL, 10.1 in MZL, 5.4 in IC, 5.5 in MCL,
and 6.3 weeks in other entities, respectively. However, 25 %
of the patients started treatment more than 54 weeks after
primary diagnosis. The combination of bendamustine and ri-
tuximab (BR) was the most common regimen and adminis-
tered to 289 (94%) patients. In 33 (11%) of these patients, BR
was supplemented by dexamethasone or prednisone. Fourteen
(5 %) patients received bendamustine monotherapy and four
patients other combinations.
Regarding treatment regimens and lymphoma types, BR
regimen without complementing steroids (n=256) was more
frequently used in FL compared to the other lymphoma enti-
ties (88 vs. 78 %, p=0.02187).
Treatment was mostly administered at 4-week intervals.
The vast majority of patients received bendamustine on days
1 and 2 of a treatment cycle (268 pts, 87 %). The median dose
of bendamustine was 177 mg/m2 per cycle corresponding to
88.4mg/m2 on days 1 and 2. Bendamustine doses were evenly
distributed over the first 6 cycles. Median dose of
bendamustinemonotherapy was 133mg/m2. At least one dose
modification of bendamustine was documented in 79 (26 %)
patients, a treatment delay (also) in 79 (26 %) patients. The
occurrence of side effects was specified as the most frequent
reason for a treatment delay (51 %).
Themedian dose intensity of bendamustine was 165mg/m2
per 4 weeks for all treatment regimens overall, 166 mg/m2 per
4 weeks for BR on its own, and 132 mg/m2 per 4 weeks for
bendamustine monotherapy. Median relative dose intensity
was 0.9 for BR i.e., the proportion of the actual dose intensity
in relation to the dose intensity as recommended by consensus
guidelines (assuming bendamustine at 90mg/m2 on days 1 and
2 of a 4-0week cycle) [5, 16]. The median number of
bendamustine-based therapy was 6 cycles and did not differ
by lymphoma type. In contrast, themean number of cycles was
5.3 (+/− 1.5) for all, 5.5 (±1.4) for FL, 5.3 (±1.3) for MZL, 4.8
(±1.7) for IC, 5.1 (±1.6) for MCL, and 5.8 (±0.6) for others.
Maintenance therapy with rituximab following termination
of bendamustine-based therapy was planned for 104 (33.9 %)
patients and more frequently for patients with FL (81 of 142,
53 %; p=0.0001).
Best response
Complete response (CR) was documented as best response in 120
(43 %) patients and partial response in 121 (43 %) patients, corre-
sponding to an overall response rate (ORR) of 86 % (95 % con-
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Fig. 1 Trial profile
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patients (6 %), best response was reported as stable disease,
resulting in a disease control rate of 92 % (95 % CI 88–95). Ten
patients (4%) did not respond to treatment.Median andmean time
to best response was 4.5 months overall (n=240) and was com-
parable across lymphoma entities. ORR was 90 % in FL, 85 % in
MZL, 78 % in IC, and 76 % in MCL. An overview of best
response overall and by lymphoma type is displayed in Table 3.
Interestingly, 13 of those 14 patients (ORR=93 %) under
bendamustine monotherapy showed a response. BR (n=263)
resulted in an ORR of 85 %. The ORR for the BR regimen
without supplementation (n=230) was 86 % compared to
79 % of the steroid supplemented BR regimen (n=33).
ORR was determined to be influenced by the variable Bage
at therapy onset^ (p=0.0117; odds ratio=0.9414) using a lo-
gistic regression model.
For evaluation of response, most of all, computed tomog-
raphy (CT) was used (in 60 % of patients), followed by labo-
ratory assessments (51 %), sonography (47 %), clinical exam-
ination (43 %), and bone marrow biopsy (10 %) (each method
used at least once per patient during the observation period,
multiple answers possible).
Safety
A total of 429 bendamustine-related side effects of any grade
were recorded. The majority of side effects resolved, and only
15 % persisted until the end of the observation period. Overall,
161 (50 %) of 323 patients (safety population) experienced at
least one side effect. The most frequently reported CTCAE cat-
egories were blood/bone marrow (35 %), gastrointestinal
(13 %), constitutional symptoms (8 %), dermatology/skin
(5 %), neurology (3 %), infections (2 %), allergy/immunology,
and pulmonary/upper respiratory (1 % of patients, respectively).
Fifty-four (17 %) patients experienced side effects of grade 3
(n=47, 15 %) or grade 4 (n=7, 2 %). Most frequently reported
CTCAE categories for grade 3/4 events were blood/bone mar-
row (n=43, 13 %), followed by infections (n=5, 2 %), constitu-
tional symptoms (n=3, 1 %), and gastrointestinal (n=2, 1 %) as






















Age Mean±SD 69±12 65±12 70±11 72±9 74±12 73±11
Median 71 68 71 71 76 75
Range 27–92 37–87 49–92 52–88 27–88 50–86
Charlson score Median 0 0 0 0 0 1.5
N (%) N (%) N (%) N (%) N (%) N (%)
Age groups <65 years 106 (35) 69 (45) 18 (35) 10 (21) 5 (14) 4 (22)
≥65 years 201 (66) 85 (55) 34 (65) 37 (79) 31 (86) 14 (78)
ECOG PS 0 131 (43) 76 (49) 19 (37) 22 (47) 9 (25) 5 (28)
1 139 (45) 64 (42) 24 (46) 20 (43) 22 (61) 9 (50)
2 16 (5) 2 (1) 6 (12) 4 (9) 3 (8) 1 (6)
3 1 (0) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0)
Not performed 20 (7) 11 (7) 3 (6) 1 (2) 2 (6) 3 (17)
Sex Male 152 (50) 67 (44) 26 (50) 26 (55) 22 (61) 11 (61)
Female 155 (50) 87 (57) 26 (50) 21 (45) 14 (39) 7 (39)
Ann Arbor stage (n=260)b I 12 (5) 10 (7) 1 (2) 1 (3) 0 (0)
II 39 (15) 21 (14) 11 (21) 6 (17) 1 (6)
III 70 (27) 51 (33) 8 (15) 7 (19) 4 (22)
IV 130 (50) 69 (45) 29 (56) 20 (56) 12 (67)
Unknown 9 (3) 3 (2) 3 (6) 2 (6) 1 (6)
B symptoms Yes 73 (24) 29 (19) 15 (29) 9 (19) 12 (33) 8 (44)
No 219 (71) 122 (79) 34 (65) 36 (77) 19 (53) 8 (44)
Unknown 15 (5) 3 (2) 3 (6) 2 (4) 5 (14) 2 (11)
SD standard deviation, PS performance status
a Other lymphoma entities comprised lymphocytic lymphoma (n=8), not otherwise specified indolent NHL (n=6), lymphoplasmocytoid lymphoma
(n=2), hairy cell leukemia (n=1), and follicular lymphoma 3a (n=1)
b Excluding immunocytoma
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well as cardiac arrhythmia, metabolic/laboratory, and
musculoskeletal/soft tissue for one patient each, respectively.
Two grade 5 toxicities were documented. One death was
associated with thrombocytopenia. The reason of death in the
other case was unknown. Overall, there were 71 hospitaliza-
tions documented. Of those, 11 (15 %) were reported to be
therapy-induced (by any of the agents administered), 12
(17 %) caused by the underlying malignant disease, and 10
(14 %) due to planned (elective) therapeutic or diagnostic
interventions. Other frequently reported reasons for hospital
admission were cardiac disease (n=11, 29 %), infections (n=
10, 26 %), and gastrointestinal disease (n=5, 13 %) which did
not necessarily have to be related to lymphoma treatment.
Eleven serious adverse drug reactions for bendamustine
were documented for ten patients according to the following
CTCAE categories: constitutional symptoms (3), infection
(3), blood/bone marrow (2), cardiac arrhythmia (1), gastroin-
testinal disorders (1), and death (not categorized, 1).
With regard to the safety set, 15 cases of death were docu-
mented during the observation period, 4 of these concerning
patients with CLL. Reason for death was documented to be
the underlying tumor disease for six patients and concomitant
disease for two patients. Suspected relationship to therapy with
bendamustine and/or rituximab was documented for one patient
each. For four patients, cause of death was documented Bdue to
other causes^ and for one patient Bcause of death unknown^.
Discussion
In awareness of the inherent limitations of cross-trial compar-
isons, in particular between non-interventional and controlled
interventional clinical trials, we aimed to evaluate if the effec-
tiveness and safety of bendamustine as first-line treatment for
indolent and mantle cell lymphomas as reported from clinical
trials are representative for its use in routine clinical practice.
In clinical routine, bendamustine was predominantly given
in combination with rituximab and at a median dose of 88 mg/
m2 on days 1 and 2 at 4-week intervals which is in line with
current consensus guidelines [16] and corresponds to the BR
regimen evaluated in the first-line phase III trial reported by
Rummel et al. [13]. Compared to the population of this rele-
vant phase III trial, our patients were older (median age 71 vs.
64 years), less patients presented with stage IV disease (53 vs.
77 %), and fewer patients had B symptoms, bone marrow
involvement, or extranodal disease. The proportion of the dif-
ferent lymphoma types was comparable with the exception of
a somewhat lower proportion of patients with MCL. First-line
bendamustine-based therapy in clinical routine practice result-
ed in a similar ORR (86 %) and CR (43 %) compared to
Rummel et al. (93 and 40 %, respectively) [13], and patients
with all lymphoma types had a similar benefit from treatment.
Of note, there was no independent review in our trial which
may have led to an overestimation of response. The limited




Bone marrow involved Yes 121 (39)
Extranodal disease Yes 186 (61)
No 103 (34)
Unknown 18 (6)
LDH>ULN Yes 109 (36)
No 182 (59)
Unknown 16 (5)
Hemoglobin <12 g/dl Yes 119 (39)
No 187 (61)
Unknown 1 (0)
IPI ≥1 risk factor 300 (98)
≥2 risk factors 227 (74)
≥3 risk factors 107 (35)
FLIPI only follicular lymphoma (n=154) Low risk 37 (24)
Intermediate risk 59 (38)
High risk 58 (38)
LDH lactate dehydrogenase in serum, ULN upper normal limit, IPI Inter-
national Prognostic Index, FLIPI follicular lymphoma international prog-
nostic index















All entities (n=281) 120 (43) 121 (43) 17 (6) 10 (4) 13 (5) 241 (86) 258 (92)
Follicular lymphoma (n=142) 67 (47) 61 (43) 5 (4) 5 (4) 4 (3) 128 (90) 133 (94)
Marginal zone lymphoma (n=46) 21 (46) 18 (39) 4 (9) 0 (0) 3 (7) 39 (85) 43 (94)
Immunocytoma (n=45) 14 (31) 21 (47) 5 (11) 1 (2) 4 (9) 35 (78) 40 (89)
Mantle cell lymphoma (n=33) 10 (30) 15 (46) 2 (6) 4 (12) 2 (6) 25 (76) 27 (82)
Other entities (n=15) 8 (53) 6 (40) 1 (7) 0 (0) 0 (0) 14 (93) 15 (100)
CR complete response,PR partial response, SD stable disease,PD progressive disease,ORR overall response rate,DCR disease control rate (CR+PR+SD)
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follow-up of our study precludes further comparisons regard-
ing progression-free survival or overall survival.
The reported side effects reflect the known safety profile of
bendamustine. Overall, toxicity and, in particular,
hematotoxicity reported in our trial was markedly lower than
what has been reported for BR in first-line [13] or even from
B or BR in rituximab-refractory NHL [8–12]. This probably has
to be attributed to the non-interventional character of our study
and a significant amount of underreporting of side effects that
did not result in any therapeutic intervention. The short follow-
up of our study does not allow an assessment of long-term
toxicity. Yet, we think it is justified to state that in our study,
first-line therapy of patients with indolent NHL or mantle cell
lymphoma with bendamustine was manageable and well
tolerated.
In conclusion, effectiveness and tolerability of
bendamustine-based first-line therapy in patients with indo-
lent lymphoma and mantle cell lymphoma were assessed as
favorable in this non-interventional trial and were at least
comparable to reported outcomes of recent literature. Our data
are in alignment with the relevant treatment guidelines and
recognize bendamustine-based therapy as a valid and valuable
standard of care for patients with indolent lymphoma and
mantle cell lymphoma in routine clinical practice.
Integrity of research and reporting
The non-interventional study was approved by an appropriate
ethics committee. All patients had to provide signed informed
consent before their inclusion in the study.
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